1. Home
  2. PBMWW vs VCEL Comparison

PBMWW vs VCEL Comparison

Compare PBMWW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBMWW
  • VCEL
  • Stock Information
  • Founded
  • PBMWW N/A
  • VCEL 1989
  • Country
  • PBMWW Canada
  • VCEL United States
  • Employees
  • PBMWW 10
  • VCEL N/A
  • Industry
  • PBMWW
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PBMWW
  • VCEL Health Care
  • Exchange
  • PBMWW Nasdaq
  • VCEL Nasdaq
  • Market Cap
  • PBMWW N/A
  • VCEL N/A
  • IPO Year
  • PBMWW N/A
  • VCEL 1997
  • Fundamental
  • Price
  • PBMWW $0.02
  • VCEL $48.85
  • Analyst Decision
  • PBMWW
  • VCEL Strong Buy
  • Analyst Count
  • PBMWW 0
  • VCEL 8
  • Target Price
  • PBMWW N/A
  • VCEL $63.00
  • AVG Volume (30 Days)
  • PBMWW N/A
  • VCEL 406.9K
  • Earning Date
  • PBMWW N/A
  • VCEL 05-07-2025
  • Dividend Yield
  • PBMWW N/A
  • VCEL N/A
  • EPS Growth
  • PBMWW N/A
  • VCEL N/A
  • EPS
  • PBMWW N/A
  • VCEL 0.20
  • Revenue
  • PBMWW N/A
  • VCEL $237,224,000.00
  • Revenue This Year
  • PBMWW N/A
  • VCEL $23.23
  • Revenue Next Year
  • PBMWW N/A
  • VCEL $24.41
  • P/E Ratio
  • PBMWW N/A
  • VCEL $247.80
  • Revenue Growth
  • PBMWW N/A
  • VCEL 20.10
  • 52 Week Low
  • PBMWW N/A
  • VCEL $39.12
  • 52 Week High
  • PBMWW N/A
  • VCEL $63.00
  • Technical
  • Relative Strength Index (RSI)
  • PBMWW N/A
  • VCEL 35.40
  • Support Level
  • PBMWW N/A
  • VCEL $47.08
  • Resistance Level
  • PBMWW N/A
  • VCEL $52.06
  • Average True Range (ATR)
  • PBMWW 0.00
  • VCEL 2.76
  • MACD
  • PBMWW 0.00
  • VCEL -0.38
  • Stochastic Oscillator
  • PBMWW 0.00
  • VCEL 15.97

About PBMWW Psyence Biomedical Ltd. Warrant

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Share on Social Networks: